Like many great things, it started with a spark, an idea and hope.

Our hope was to empower

and enable the brightest minds to tackle some of the world’s most challenging problems in health.
We’re pleased to share that we are making progress and it's because of the company we keep. Just
six short years after our founding, Johnson & Johnson Innovation, JLABS has not only experienced
significant growth through collaborative expansions and new initiatives, but the impact JLABS and the
companies are having on the innovation ecosystem is undeniable. We are proud to share an update
with our community and perhaps give you a glimpse into the amazing work
and the passion that’s driving innovation across JLABS.

But first, let’s do the numbers – we’ve grown to 12 JLABS locations

across the globe – we have awarded nearly $6 million in awards
via QuickFire Challenges; we now have 450+ companies
in our JLABS ecosystem who have secured $11+ billion in
financing. We’re extremely proud of our collective progress
filled with promising milestones because it represents the
science, the ingenuity and the heart of our community
who are focused on our vital mission: to positively impact
the trajectory of health for humanity.

Melinda Richter
Global Head of Johnson & Johnson Innovation, JLABS
JLABS is experiencing substantial demand and growth around the
world – adding locations, deploying new vehicles for entrepreneurs, and
delivering enhanced programming like the Global CEO Summit, Inside
Scoop, and Health Tech @ JLABS, all while connecting our global network of
investors, resources and experts. With this growth, we’ve seen a dramatic
increase in diversity in the companies, technologies and talent entering the
JLABS ecosystem.
 Established Locations
JLABS @ M2D2
Newest Locations JLABS @ LabCentral

JLABS @ SSF JLABS @ Toronto JPOD @ Boston

JLABS @ MBC
JLABS @ NYC

JPOD @ Philadelphia
JLABS San Diego

JLABS @ TMC
Beerse was the home of a young researcher named Dr. Paul Janssen, who started a company with a
loan from his father of 50,000 Belgian francs and workspace on the third floor of the family business.
That lab would go on to achieve great things: delivering more than 80 medicines that saved millions
of lives. Beerse is now home of the first JLABS in Europe to give other innovators the opportunity to
follow in Dr. Paul Janssen’s footsteps.

JLABS @ BE

JLABS @ Shanghai
Opening 2019

“JLABS is bringing its unparalleled world-class R&D resources and

networks to the research community in Shanghai – and we are honored
to witness their great impact on the innovations born here.”
Michelle Li Sun |Managing Director, Head, Healthcare, Ping An Capital
Total JLABS community increased ...

We’ve received ... ... from entrepreneurs in ...

“JLABS has provided us a home in the heart of
Texas complete with rocket fuel to power our
development,” said John Zellmer, co-founder and
CEO of Intelligent Implants.
Imagine if doctors could not only monitor your
bone growth after spinal surgery in real time, but
also speed it up, redirect it remotely and help you
heal quicker. According to Intelligent Implants,
they’re building that capability with wireless
implantable electronics.
Johnson & Johnson Innovation scouts first spotted
the company’s founders in Shenzhen, China, and
connected them to JLABS @ TMC for access to
specialized equipment and expertise for medical
device companies. Since joining JLABS in March
2017, Intelligent Implants has gained connections
to advance their technology and has been able to
leverage their portfolio status to attract funding –
including investments from TMC Venture Fund and
AngelMD Catalyst Fund. The company also won
the CDI @ TMC QuickFire Challenge recognizing
the game-changing potential of their solution.
“By introducing electronics and real-time
analytics into the orthopedic business, our
technology could help hundreds of thousands
of people every year,” Zellmer said.
The tragedy of rare and chronic diseases is that
people living with these conditions often die of
complications rather than the diagnosed condition
itself. Artificial Intelligence (AI) could change this
situation. Medopad, the winner of our Metabolic
Disease QuickFire Challenge in Singapore, uses
AI to do just that. Their platform, which covers
a wide variety of disease areas, generates
predictive insights to detect life threatening
medical conditions, develop more efficient drugs
and deliver a more personalized approach to
population health by transforming the way
patients and data interact with clinicians.
The London-based company, with offices at JLABS
@ NYC, has attracted attention from businesses,
governments and organizations around the
world, completing more than $130 million in
commercial deals in China alone. Medopad
is also collaborating with Actelion, a Janssen
Pharmaceutical Company of Johnson & Johnson,
to support patients living with pulmonary arterial
hypertension, as well as Johnson & Johnson Vision
Care, to enhance eye health.
Programs & Community | JLABS has produced 400+ events this year in 47 cities around the world,
attracting more than 19,000 guests to our community, with more than 76,000 visitors participating in
our programs over the past six years. We’ve added new programs to help our ecosystem members
connect to each other and to vital stakeholders like investors who can support their growth. These
events include the Inside Scoop, where companies pitch to a global audience, and the Global CEO
Summit, where JLABS CEOs connect with each other along with other partners, investors and Johnson
& Johnson executives.

Our Inside Scoop attracted ...

&

The inaugural Global CEO Summit in 2017 drew ...

... and spurred many partnering conversations.

“When people look back and wonder where did that great idea come
from, that ended up curing a disease, they’re going to say it all started
right here – in New York, because of this innovative initiative.”
Kathy Hochul | New York Lieutenant Governor
JLABS is attractive to a continuum of innovators from first-time entrepreneurs
to serial scientific founders representing diverse experiences across academic,
start-up, corporate, and venture worlds. Their common bond is their mission to
develop solutions across a broad range of healthcare sectors, to enhance and save
lives. Indeed, we recognized that much of the world’s creative potential and passion
was untapped, so we created the QuickFire Challenges, a crowdsourcing platform
to reach every type of innovator no matter where they lived, no matter who they
were. All they needed was to be inspired to advance solutions for health and to
demonstrate an idea, a plan that gave us a reason to believe. We’re proud to curate
a robust, industry-leading network of leaders and companies from all corners of the
earth who are creating the future of health.
“My introduction to JLABS @ Toronto
was through the Investor
Hub as an investor,
where we funded three
companies. Based on
that success, when I
decided to start my
own company,
I applied to JLABS.”

Drew Taylor
CEO of Acorn BioLabs, Lead Medical Researcher
JLABS has launched a total of ...

awarding

• MObile wellness • DRiving device • lung cancer innovation • Robotics & Digital
innovation Surgery
• first 1000 days • lab coat of the future
• Patient Adherence • JOhnson & Johnson
• Carcinogenic • Advancing the Safe Use nurses innovate
Exposure meter • Digital Beauty of Healthcare Products

We have received applications from ...

These competitions span many areas of interest including medical device, pharma, consumer, health
tech, supply chain and cross-sector opportunities.
 Caleb Hernandez clearly remembers the moment
he almost lost a patient because of a dosing error.
The emergency room physician recalls seeing a
nurse about to administer 10 times the amount
of medicine to a 5-year old girl, and called out
to stop. That saved her life, but it also made him
realize a desperate need to change the industry
– where medical errors are now the third leading
cause of death in the U.S., according to a study by
John Hopkins.
The problem
arises because
doctors and
nurses use
different
systems to
measure
medicines,
and the complex math needed to convert one
standard to the other based on the patient’s weight
can lead to mistakes, especially in emergency
situations. Hernandez took a different, color-coded
system already used by healthcare professionals and
placed it on syringes. His company, Certa Dose, will
deliver its first two products this year.
“I thought, ‘wouldn’t it be
great if docs and nurses
could be on the same
page?’ But everyone is
using different units.”
–Caleb Hernandez, President & CEO of Certa Dose
Hernandez, a refugee from El Salvador, arrived in
the U.S. at the age of 3 when his parents sought
asylum after fleeing civil war. He first connected with
J&J after scouts heard his pitch at a SXSW event. In
December 2017, Johnson & Johnson Innovation
named Certa Dose the winner of its Advancing the
Safe Use of Healthcare Products QuickFire Challenge.
Subsequent to the award, Certa Dose raised an
additional $5 million and move the company to
JLABS @ NYC in preparation for the launch of its first
FDA approved product line.
“Envisagenics combines biology with machine
learning, so finding the right infrastructure
and the right community in New York City
was essential. Being able to design therapies
in-house is important to advance our research.”
Diagnosing the genetic cause of a disease could take
months, if not years. Maria Luisa Pineda is hard at
work to reduce that time to just hours. According to
Dr. Pineda, her company, Envisagenics Inc., part of
JLABS @ NYC’s initial cohort, is combining Artificial
Intelligence, high performance
computing and RNA sequencing
data from patients to discover
causes – and treatments
– for some of the 370
devastating diseases
induced by RNA splicing
errors, including acute
myeloid leukemia,
breast cancer and ALS
(amyotrophic lateral
sclerosis).
Pineda, a native
of Colombia, has
always gravitated
towards science
because she
likes tackling
difficult problems. This first-time entrepreneur
heard about JLABS through her investors, who
recommended the incubator network after their
other portfolio companies in JLABS had successful
exits. Now, as a resident company and winner
of the Artificial Intelligence for Drug Discovery
QuickFire Challenge, Pineda appreciates the
mentorship Envisagenics is receiving.
“I’ve been able to present
my technology to J&J’s
CEO, Alex Gorsky, and
have a one-on-one with
Paul Stoffels, J&J’s CSO.
It’s been invaluable to
get feedback from them
in order to advance our
science and scale
the business.”
– Maria Luisa Pineda, CEO of Envisagenics, Inc.
a JLABS @ NYC resident company
With more than a dozen founders already on their second
company in JLABS, our companies are a mix of …

Diversity of residents:

compared to < 1% in the life sciences industry*

compared to 8% for STEM companies*

* Report by the Small Business Administration
With the commitment and backing of Johnson & Johnson Innovation – JJDC, Inc., JLABS created
Investor Hubs, a network of global investors, in each site to mentor and potentially invest in JLABS
portfolio companies.

The number of investors has increased to ...

JLABS works with external partners to provide a strong platform of resources for our companies
for insurance, accounting, banking, legal & CROs.

providing business services

One of the emerging areas of research in healthcare is the microbiome – the billions of bacteria and
microorganisms that inhabit our guts and coat our skin may play a role in many different areas of our
health. JLABS has more than 20 microbiome companies investigating treatments for areas such as cancer,
neurology, skin health, infectious diseases and nutrition.
Holobiome, a JLABS @ LabCentral company informative events on subjects such as venture
working on developing new microbiome therapies, financing and commercialization, and connect
signed a collaboration with Janssen Research & with leading experts within the consumer and
Development in January 2018 to treat diseases of drug development arenas.
the central and enteric nervous systems. The
company is investigating whether bacteria
could be used to
“Interacting with the
create a unique other JLABS companies
probiotic or
over-the- has provided us a global
counter
medicine that
network that would have
addresses been impossible to curate
sleeplessness.
on our own. We've been
Phil Strandwitz,
co-founder
exposed to tremendous
and CEO of resources within the
Holobiome,
said since J&J umbrella – we feel
joining JLABS
in early 2018,
like we're part of a big
he’s been able biotechnology family.”
to attend
– Phil Strandwitz, co-founder & CEO of Holobiome
In the future, you may owe your good health to a chicken – or humanized chicken antibodies, to be
exact. That’s because chickens offer potentially more antibody diversity than other animal models used
in drug development, which could lead to better targets for life-saving therapies.

This is why a Johnson & Johnson Innovation scout conference outside of Montreal. When the
in Canada was intrigued by Immune Biosolutions company became one of JLABS @ Toronto’s first
when they met at resident companies, she connected them with
a remote life several JPALS across Johnson & Johnson which
science culminated into an agreement with Janssen Biotech
to identify and develop therapeutic antibodies for
multiple targets areas, including cancer.

“Immune Biosolutions was

persistent and passionate,
and once inside JLABS,
we were able to put the
company in front of
the right people, and
ultimately sign a deal.”
– Jennifer Hamilton, Senior Director, New
Ventures, J&J Innovation (Canada). Advisor,
J&J Global Community Impact, Impact Investing
JLABS companies have access to a wealth of J&J expertise through the JPALS program. JPALS are
experts within J&J that provide mentorship, access to resources, internal assets and contacts to support the
companies growth.

MENTORS
across

“As an alumni, JLABS offered to continue to mentor us. Through the

JPALS program, we connected with J&J’s global regulatory experts whose
deep knowledge and experience is invaluable to us.”
Wendye Robbins | President & CEO, Blade Therapeutics
“We chose JLABS because of the access they provide to medical
device experts, as well as to internal Johnson & Johnson leaders.
The guidance we’ve received is helping us refine our go-to-market
strategy; this sales and distribution strategy is something we
couldn’t have created on our own.”
Jessica Traver | CEO of Intuitap, a JLABS @ TMC resident
“JLABS has a deeply understood start-up culture, and has exquisitely
tuned its model to the new world. This is an unusual model within
pharma, where most companies have preferred ‘sameness with
difference’ — doing something that they might have always done,
but under a different name.”
Mike Rea | CEO of Idea Pharma
JLABS companies are hot on the move, raising capital, accelerating
development and partnering with commercial organizations.
Increasingly our companies are also entering the public markets, entering
into clinical trials and reaching commercial milestones making their solutions
available to people all over the world.
“At Johnson & Johnson Innovation,
our goal is to bring forth highly
differentiated healthcare solutions
that extend and improve lives.
To do this, we collaborate
with innovators and
entrepreneurs all
over the world to
advance the best
science, wherever
it exists.”

Paul Stoffels
Vice Chair of the Executive Committee and
Chief Scientific Officer, Johnson & Johnson
During the past six years, JLABS companies have
collectively secured ...

Of JLABS residents & alumni ...

&

*Based on Survey Results (261 responses)

Our companies have grown beyond our walls ...

securing

Every 65 seconds, someone develops Alzheimer’s disease, according to the Alzheimer’s Association. Yet the
condition can start to make changes in the brain decades before our current, paper-based tests can detect
it. According to Winterlight Labs, a JLABS @ Toronto resident company, they have the technology that can
spot signs of cognitive decline much earlier and within minutes. The company uses artificial intelligence
to analyze speech and language patterns to help Helping to foster cutting-edge technologies
detect and monitor mental diseases. Early detection and high potential collaborations for health is
of Alzheimer’s could save $7.9 trillion in medical why JLABS exists. As we grow into new markets
and care costs alone, according to the Alzheimer’s with new innovation vehicles to support radical
Association. The potential for this technology to new ideas and technologies from every type of
have an impact for care and costs prompted Janssen innovator, we’re excited about our collective
Research & Development to partner with Winterlight potential to provide better, faster, more
to progress the development of the technology. accessible and affordable options for care.
Improving lives requires both solving complex
scientific problems and convincing funders to
take a leap of faith. BlackThorn Therapeutics,
one of our JLABS @ South San Francisco alumni
that is discovering and developing targeted
treatments for neurobehavioral disorders, has
been knocking both of these out of the park. In
addition to raising $54 million in financing, in June
of 2018, the company successfully enrolled its
first healthy volunteer in a Phase 1 study targeting
brain circuits that modulate the negative effects
of stress on behavior. That important milestone
required a significant investment, part of which
came from Johnson & Johnson Innovation, JJDC
in 2016. Bill Martin, Chief Scientific Officer of
BlackThorn, credits his journey with JLABS to
bringing together all the elements necessary to
progressing and funding BlackThorn’s science.
“It's hard to start companies for many reasons
people don't appreciate,” Martin said. “Many
trivial things end up distracting you from the
science and funding, but if you're working
with others in a non-competitive way, you
can leverage insights, learnings, partners and
services to become more focused on what
matters. There's a great sense of collegiality
so even if you’re a small team, you feel like
you're a company of 50 or 100 people because
you're part of a larger community.”
Alector, an alumni of JLABS @ MBC, has been
making headlines for its bold mission to “develop
therapies that empower the immune system
to cure neurodegeneration.” Whereas many in
the industry have abandoned their work in the
field of Alzheimer’s, a devastating disease that
affects so many people around the world, Alector
continues to double down on its mission to cure
it – and has attracted interest across the industry.
Alector announced a $1.2 billion partnership
with a $225 million up-front payment  in October
2017, and a $133 million private funding round
in July of 2018. The company is now advancing
three new medicines into human clinical trials.
Arcturus Therapeutics, now a public company as
of November 2017, is working on treatments and
vaccines for some of the most deadly, debilitating
diseases in the world, such as Hepatitis B, non-
alcoholic steatohepatitis, cystic fibrosis, and rare
liver diseases. Johnson & Johnson’s Janssen R&D
organization has signed multiple collaborations
with the company as well, with the first agreement
originating when Arcturus was just two young
guys with a dream and an idea. Co-founders Joe
Payne and Pad Chivukula, are amazed at how far
they’ve come in five years since they moved into
JLABS San Diego.
Of JLABS residents & alumni, there have been ...

are STILL IN

Deals with Johnson & Johnson Family of Companies:

“Johnson & Johnson has created a remarkably successful program that
enables them to support entrepreneurs without imposing constraints.”
- Standish Fleming | Founding Managing Member of Forward Ventures

“JLABS, the expression of J&J's innovation initiative, has been a powerful

force for good in the entrepreneur community, providing both a valuable
resource as well as an innovation on-ramp to what can seem like a large and
imposing global organization. Today, in large measure due to JLABS and
the folks who are part of the J&J Innovation community, J&J has earned a
reputation as a curious and exploratory organization keenly interested in
connecting with front-line innovators and promising startups.”
David A. Shaywitz, MD, PhD | Senior Partner, Takeda Ventures, Inc.
“We literally quit our jobs, and started the company with just a few
thousand dollars. But we also had a dream, and an ambition to do
something great in the world of RNA medicines. Since then, we've
grown the company, exceeded triple digit millions in valuation,
and are trading on the NASDAQ. We are truly humbled to be a
part of this exciting story.”
Joe Payne | CEO of Arcturus

“Sometimes, I think JLABS can actually see the future! It’s clear that
their vision, methodology and partnerships are clearly building that
future today!”
John Nosta | Digital Health Philosopher